QLT, Inc (NASDAQ: QLTI) CEO InterviewQLT, Inc (NASDAQ: QLTI) CEO InterviewThis interview has expired. Special deals for our readers Be a more profitable investor: Get an Equifax 3-in-1 Credit Report Now! Why are you still paying too much with Schwab, and and E-trade?? Step up to the #1 discount broker: TradeKing. Invest Smarter! Get 4 Bonus Weeks of Investor’s Business Daily Digital Edition! LifeLock is the only Identity Theft Prevention Solution backed by a one-million dollar guarantee!Click here to get a 10% discount. Get FICO Score Watch Now! Click here to get access to powerful investing tools only available at Investor’s Business Daily. Get a free look at Jim Cramer’s Action Alerts PLUS portfolio. Click here QLT, Inc QLT Inc. (QLT), is a global biopharmaceutical company engaged in the business of discovering, developing and commercialization of therapies. QLT has two commercial products, Visudyne and Eligard. Visudyne utilizes photodynamic therapy (PDT), to treat the eye disease known as wet age related macular degeneration (wet AMD), the cause of blindness in people over the age of 55 in North America and Europe. Visudyne is also used for the treatment of subfoveal choroidal neovascularization (CNV) due to pathologic myopia, or severe near-sightedness, and presumed ocular histoplasmosis or other macular diseases. The Eligard product line includes one, three, four and six month commercial formulations of Atrigel technology combined with leuprolide acetate. Leave a Reply |
|
Standard Podcast: 
WSR Recommends |
||
| Special Deal for Our Readers (That’s You!) | Jim Cramer: The Clown That Makes You Money | Get Rich with Fibonacci. Learn How to Use Fibonacci Analysis to Trade Better. |
